Suppr超能文献

缓激肽受体 B1 抑制通过减少血脑屏障渗漏和炎症反应保护小鼠局灶性脑损伤。

Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation.

机构信息

Department of Neurosurgery, University of Würzburg, Würzburg, Germany.

出版信息

J Cereb Blood Flow Metab. 2010 Aug;30(8):1477-86. doi: 10.1038/jcbfm.2010.28. Epub 2010 Mar 3.

Abstract

Kinins are proinflammatory and vasoactive peptides that are released during tissue damage and may contribute to neuronal degeneration, inflammation, and edema formation after brain injury by acting on discrete bradykinin receptors, B1R and B2R. We studied the expression of B1R and B2R and the effect of their inhibition on lesion size, blood-brain barrier (BBB) disruption, and inflammatory processes after a focal cryolesion of the right parietal cortex in mice. B1R and B2R gene transcripts were significantly induced in the lesioned hemispheres of wild-type mice (P<0.05). The volume of the cortical lesions and neuronal damage at 24 h after injury in B1R(-/-) mice were significantly smaller than in wild-type controls (2.5+/-2.6 versus 11.5+/-3.9 mm(3), P<0.001). Treatment with the B1R antagonist R-715 1 h after lesion induction likewise reduced lesion volume in wild-type mice (2.6+/-1.4 versus 12.2+/-6.1 mm(3), P<0.001). This was accompanied by a remarkable reduction of BBB disruption and tissue inflammation. In contrast, genetic deletion or pharmacological inhibition of B2R had no significant impact on lesion formation or the development of brain edema. We conclude that B1R inhibition may offer a novel therapeutic strategy after acute brain injuries.

摘要

激肽是一种促炎和血管活性肽,在组织损伤时释放,并通过作用于离散的缓激肽受体 B1R 和 B2R,可能导致脑损伤后神经元变性、炎症和水肿形成。我们研究了 B1R 和 B2R 的表达及其抑制作用对右侧顶叶皮质局灶性冷冻损伤后小鼠的损伤大小、血脑屏障(BBB)破坏和炎症过程的影响。B1R 和 B2R 基因转录本在野生型小鼠损伤半球中显著诱导(P<0.05)。B1R(-/-) 小鼠在损伤后 24 小时的皮质损伤和神经元损伤体积明显小于野生型对照(2.5+/-2.6 与 11.5+/-3.9 mm(3),P<0.001)。在损伤诱导后 1 小时用 B1R 拮抗剂 R-715 处理也会降低野生型小鼠的损伤体积(2.6+/-1.4 与 12.2+/-6.1 mm(3),P<0.001)。这伴随着 BBB 破坏和组织炎症的显著减少。相比之下,B2R 的基因缺失或药理学抑制对损伤形成或脑水肿的发展没有显著影响。我们得出结论,B1R 抑制可能为急性脑损伤后的治疗提供新策略。

相似文献

1
Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation.
J Cereb Blood Flow Metab. 2010 Aug;30(8):1477-86. doi: 10.1038/jcbfm.2010.28. Epub 2010 Mar 3.
3
Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
J Autoimmun. 2011 Mar;36(2):106-14. doi: 10.1016/j.jaut.2010.11.004. Epub 2011 Jan 8.
4
Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation.
J Cereb Blood Flow Metab. 2012 Sep;32(9):1747-56. doi: 10.1038/jcbfm.2012.62. Epub 2012 May 9.
7
Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice.
Tuberculosis (Edinb). 2018 Mar;109:1-7. doi: 10.1016/j.tube.2018.01.003. Epub 2018 Feb 2.
8
Primary Role for Kinin B and B Receptors in Glioma Proliferation.
Mol Neurobiol. 2017 Dec;54(10):7869-7882. doi: 10.1007/s12035-016-0265-9. Epub 2016 Nov 16.
9
Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.
J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.

引用本文的文献

1
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms.
Front Mol Med. 2023 Jan 4;2:1035290. doi: 10.3389/fmmed.2022.1035290. eCollection 2022.
2
Delayed plasma kallikrein inhibition fosters post-stroke recovery by reducing thrombo-inflammation.
J Neuroinflammation. 2024 Jun 13;21(1):155. doi: 10.1186/s12974-024-03149-w.
4
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective.
J Cell Mol Med. 2024 Jan;28(2):e17993. doi: 10.1111/jcmm.17993. Epub 2023 Oct 17.
8
Nanoparticle-based drug delivery for the treatment of traumatic brain injury.
Expert Opin Drug Deliv. 2023 Jan;20(1):55-73. doi: 10.1080/17425247.2023.2152001. Epub 2022 Dec 6.
10
Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.
Mol Immunol. 2022 Oct;150:99-113. doi: 10.1016/j.molimm.2022.08.008. Epub 2022 Aug 22.

本文引用的文献

1
The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.
J Cereb Blood Flow Metab. 2010 Jan;30(1):130-9. doi: 10.1038/jcbfm.2009.196. Epub 2009 Sep 23.
2
Differential effects of endothelin receptor A and B antagonism on cerebral hypoperfusion following traumatic brain injury.
Neurol Res. 2010 Mar;32(2):209-14. doi: 10.1179/174313209X414515. Epub 2009 Jun 30.
5
Combination therapies for traumatic brain injury: prospective considerations.
J Neurotrauma. 2009 Jun;26(6):925-39. doi: 10.1089/neu.2008.0794.
6
Pathophysiology of traumatic brain injury.
Mt Sinai J Med. 2009 Apr;76(2):97-104. doi: 10.1002/msj.20104.
8
Pharmacology of traumatic brain injury: where is the "golden bullet"?
Mol Med. 2008 Nov-Dec;14(11-12):731-40. doi: 10.2119/2008-00050.Beauchamp. Epub 2008 Aug 18.
9
Mechanisms of ET-1-induced endothelial dysfunction.
J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8. doi: 10.1097/FJC.0b013e31813c6cc3.
10
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
Br J Pharmacol. 2008 Mar;153(6):1105-19. doi: 10.1038/sj.bjp.0707516. Epub 2007 Oct 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验